Skip to main content

Table 2 Baseline characteristics of patients in the cohort

From: Emergency gastrointestinal surgery in patients undergoing antithrombotic therapy in a single general hospital: a propensity score-matched analysis

Variables

 

n = 732

No-matched cohort

Matched cohort

AT (n = 64)

Non-AT (n = 668)

p value

AT (n = 63)

Non-AT (n = 63)

p value

Patient-related factors

Age*

Years

51 (34–74)

83 (76–8)

47 (32–68)

 < 0.001

83 (76–87)

81 (69–87)

0.214

Sex

Male

400 (55%)

39 (61%)

361 (54%)

0.290

39 (62%)

32 (51%)

0.209

Postoperative diagnosis

Appendicitis

441 (60%)

9 (14%)

432 (65%)

 < 0.001

9 (14%)

10 (16%)

 
 

Small bowel obstruction

142 (19%)

33 (52%)

109 (16%)

 

33 (52%)

28 (44%)

 
 

UGI perforation

47 (6%)

8 (12%)

39 (6%)

 

8(13%)

9 (14%)

 
 

Cholecystitis

34 (5%)

3 (5%)

34 (5%)

 

3 (5%)

0

 
 

Large bowel perforation

30 (4%)

4 (6%)

31 (4%)

 

4 (6%)

7 (11%)

 
 

Large bowel obstruction

23 (3%)

2 (3%)

21 (3%)

 

2 (3%)

8 (13%)

 
 

Bacterial peritonitis

7 (1%)

1 (2%)

6 (1%)

 

1 (1%)

0

 
 

Gastrointestinal bleeding

6 (1%)

3 (5%)

3 (0.5%)

 

3 (5%)

1 (1%)

 
 

Others

2 (0.2%)

1 (0.2%)

1 (0.2%)

    

Charlson comorbidity index

0

572 (78%)

32 (50%)

540 (81%)

 < 0.001

32 (51%)

37 (59%)

0.174

 

1

95 (13%)

21 (33%)

74 (11%)

 

21 (33%)

13 (20%)

 
 

2

41 (6%)

9 (14%)

32 (5%)

 

9 (14%)

8 (13%)

 
 

3

13 (2%)

1 (1%)

12 (2%)

 

1 (2%)

5 (8%)

 
 

 ≥ 4

11 (2%)

1 (1%)

10 (1%)

 

0

0

 

BMI*

kg/m2

21.4 (19.0–23.8)

21.9 (18.8–24.4)

21.4 (19.1–23.7)

0.701

21.9 (18.8–24.4)

20.2 (18.4–22.9)

0.172

ASA・PS

1

356 (49%)

0

356 (53%)

 < 0.001

0

4 (6%)

0.125

 

2

306 (42%)

45 (70%)

261 (39%)

 

45 (71%)

43 (68%)

 
 

3

64 (8%)

19 (30%)

45 (7%)

 

18 (29%)

16 (26%)

 
 

4

5 (1%)

0

5 (1%)

 

0

0

 

Malignancy

yes

29 (4%)

2 (3%)

27 (4%)

0.719

2 (3%)

8 (13%)

0.048

Preoperative laboratory data

White blood cell*

/μL

12,300 (9500–15,400)

10,500 (7525–13,200)

12,600 (9600–15,600)

 < 0.001

10,600 (7600–13,300)

9900 (6800–14,500)

0.725

Hemoglobin*

g/dL

13.8 (12.5–15.0)

12.6 (11.1–14.3)

13.9 (12.6–15.1)

 < 0.001

12.6 (11.0–14.3)

13.3 (11.8–15.0)

0.147

Platelet*

 × 104/μl

23.0 (18.8–28.1)

22.0 (13.1–36.1)

19.5 (14.0–28.9)

0.455

21.7 (13.0–36.6)

19.0 (13.3–33.2)

0.742

Creatinine*

U/l

0.77 (0.64–0.94)

1.07 (0.88–1.70)

0.75 (0.63–0.91)

 < 0.001

1.06 (0.88–1.66)

0.83 (0.68–1.10)

0.003

C-reactive protein*

mg/dl

1.9 (0.23–6.81)

1.99 (0.22–9.56)

1.89 (0.23–6.65)

0.706

1.90 (0.22–8.85)

1.17 (0.13–9.31)

0.934

PT(INR) *

 

1.09 (1.02–1.19)

1.13 (1.06–1.36)

1.09 (1.02–1.17)

 < 0.001

1.13 (1.06–1.35)

1.08 (1.01–1.16)

0.005

APTT*

sec

28.8 (26.6–31.6)

29.8 (27.1–33.3)

28.7 (26.6–31.3)

0.020

29.7 (27.0–33.1)

28.0 (25.6–29.8)

0.003

  1. AT: antithrombotic therapy, *: Median (Quartile), BMI: body mass index, ASA・PS: American Society of Anesthesiologists classification of physical status
  2. PT(INR): prothrombin time-international normalized ratio, APTT: activated partial thromboplastin time
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us